Path: utzoo!attcan!uunet!decwrl!elroy.jpl.nasa.gov!ucla-cs!rhc@PacBell.COM
From: rhc@PacBell.COM (Robert Cohen)
Newsgroups: sci.med.aids
Subject: Re: Salk, etc.
Message-ID: <40703@shemp.CS.UCLA.EDU>
Date: 28 Oct 90 07:22:56 GMT
References: <40546@shemp.CS.UCLA.EDU>
Sender: news@CS.UCLA.EDU
Reply-To: rhc@PacBell.COM (Robert Cohen)
Organization: Pacific * Bell, San Francisco, CA
Lines: 18
Approved: phil@wubios.wustl.edu
Nntp-Posting-Host: squid.cs.ucla.edu
Note:	Copyright 1990 by Daniel R. Greening.  Permission granted for
Note:	non-commercial reproduction.
Archive-number: 2693

In article <40546@shemp.CS.UCLA.EDU> The.Bird@f38.n135.z1.fidonet.org (The "Bird") writes:
->I remember hearing bits of a presentation by one of the Salk associates at the
->S.F. AIDS Conference. My memory tells me that they had pretty much given up on
->the seropositive application as being ineffective.
->
->Does anyone have that presentation or a reference to it's publication? I don't
->want to spread false statements cause I "heard it somewhere".
Bird,
I can't help with the abstracts, but do know that Salk's firm(?), Immune 
Response, in La Jolla, CA is planning phase II trials with sero-positives.
Call their info line at 800-422-5448 for recorded details.

If you find out more, through the abstracts, or however, please post.
-- 
  
Robert Cohen San Francisco, California 		rhc@PacBell.COM
{att,bellcore,sun,ames,pyramid}!pacbell!rhc
work:  415-542-5517   home: 553-4033